Department of Endocrinology, Metaxa Hospital, 51 Botassi Street, 18537 Piraeus, Greece.
Endocrine. 2010 Feb;37(1):6-10. doi: 10.1007/s12020-009-9290-z. Epub 2010 Jan 6.
Tyrosine kinase receptors have been implicated in thyroid cancer. Therefore, tyrosine kinase inhibitors may be used for the treatment of advanced metastatic thyroid carcinoma. The aim is to present a case of metastatic papillary thyroid carcinoma responding to the administration of sunitinib, a multi-targeted protein kinase inhibitor. A patient presented with metastatic papillary thyroid carcinoma and hyperthyroidism. After euthyroidism was achieved the patient was treated by the administration of therapeutic radioiodine (131)I, radiotherapy and sunitinib, a multi-targeted tyrosine kinase inhibitor. Thyroglobulin levels decreased from 9,594 to 6,816 ng/ml after 1 month, 6 months later being 2,776 ng/ml. The lesion in the pelvis was 12.5 × 9 cm before treatment decreasing thereafter and the patient improved clinically. The administration of sunitinib resulted in partial disease response in a patient with progressive metastatic papillary thyroid carcinoma. Protein kinase inhibitors may prove useful in the management of advanced metastatic papillary thyroid carcinoma.
酪氨酸激酶受体与甲状腺癌相关。因此，酪氨酸激酶抑制剂可能被用于治疗晚期转移性甲状腺癌。本文旨在介绍一例转移性甲状腺乳头状癌患者，其对舒尼替尼（一种多靶点蛋白激酶抑制剂）治疗有反应。一位患者表现为转移性甲状腺乳头状癌合并甲状腺功能亢进。在甲状腺功能正常后，患者接受了放射性碘（131）I 治疗、放疗和多靶点酪氨酸激酶抑制剂舒尼替尼治疗。1 个月后，患者的甲状腺球蛋白水平从 9594 降至 6816ng/ml，6 个月后降至 2776ng/ml。治疗前骨盆中的病灶为 12.5×9cm，此后逐渐缩小，患者的临床状况得到改善。舒尼替尼的应用使进展性转移性甲状腺乳头状癌患者的病情部分缓解。蛋白激酶抑制剂可能在治疗晚期转移性甲状腺乳头状癌方面具有一定的应用价值。
